Search

Displaying results 1691 - 1700 of 10000 in total
  1. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. … Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.

    Products: TESLASCAN 0,01MMOL 50 ML FLAKON, 1 ADET
  2. Drug

    Midodrine

    go.drugbank.com/drugs/DB00211
    ApprovedInvestigational

    An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSynonyms: 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
  3. Drug

    Ferrous cation

    go.drugbank.com/drugs/DB14510
    Investigational

    Products: PLASTUFER 100 MG, PLASTUFER MITE 50 MG
  4. Drug

    Levomethadone

    go.drugbank.com/drugs/DB13515
    Investigational

    Products: Levo-Methasan 10 mg-Tabletten, L-Polamidon 5 mg Tabletten
  5. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    with at least one molecule of polyethylene glycol (MW 20 kDa) [FDA label]. … PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein.

    Products: ADYNOVATE 500®IU / VIAL, ADYNOVATE 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
  6. Drug

    Fenspiride

    go.drugbank.com/drugs/DB08979
    Investigational

    Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respirator...

    Products: OXOFEN 2 MG/ML ŞURUP ,150 ML, PASFEN 2MG/ML ŞURUP
  7. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: BRAFTOVI® 75 MG CÁPSULAS, BRAFTOVİ 75 MG SERT KAPSÜL, 42 ADET
  8. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. … to this therapeutic target.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTAS
  9. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection. … HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens

    Synonyms: N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-DIFLUOROPHENYL)ETHYL)-5,5-DIFLUORO-3B,4,4A,5-, METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO-3-(TRIFLUOROMETHYL)-3B,4,4A,5-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    for abuse in addition to a low risk of dependence [L5074]. … In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesProducts: Carisoprodol Tablets, USP, 350 mg